SSA
BMY.RT

Schonfeld Strategic Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-493,006
Closed -$341K – 2372
2020
Q4 		$341K Sell
493,006
-598,243
-55% -$1.27M ﹤0.01% 1161
2020
Q3 		$2.46M Buy
1,091,249
+620,013
+132% +$1.77M 0.05% 449
2020
Q2 		$1.69M Buy
471,236
+130,936
+38% +$472K 0.04% 451
2020
Q1 		$1.29M Buy
340,300
+201,000
+144% +$662K 0.08% 293
2019
Q4 		$419K Buy
+139,300
New +$362K 0.01% 825

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Schonfeld Strategic Advisors's BMY.RT Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 493,006 shares — an estimated $341K sold.

Schonfeld Strategic Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.46M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Schonfeld Strategic Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 493,006 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $341K.
  • Schonfeld Strategic Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.46M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.